Claims
- 1. A method of modulating sensitivity of a host to insulin and/or leptin, said method comprising:
administering to said host an effective amount of one or more active agents that alter DGAT1 activity in said host to modulate sensitivity of said host to insulin and/or leptin.
- 2. The method according to claim 1, wherein said agent decreases DGAT1 activity and said method is a method of increasing sensitivity of a host to insulin.
- 3. The method according to claim 1, wherein said agent decreases DGAT1 activity and said method is a method of increasing sensitivity of a host to leptin.
- 4. The method according to claim 1, wherein said agent increases DGAT1 activity and said method is a method of decreasing sensitivity of a host to insulin.
- 5. The method according to claim 1, wherein said agent increases DGAT1 activity and said method is a method of decreasing sensitivity of a host to leptin.
- 6. A method of modulating carbohydrate metabolism in a host, said method comprising:
administering to said host an effective amount of one or more active agents that modulate DGAT1 activity in said host and modulate carbohydrate metabolism in said host.
- 7. The method according to claim 6, wherein said carbohydrate is glucose.
- 8. The method according to claim 7, wherein said active agent modulates glucose uptake into cells of said host.
- 9. The method according to claim 8, wherein said cells are selected from muscle and liver cells.
- 10. The method according to claim 7, wherein said active agent increases glycogen synthesis in cells of said host.
- 11. The method according to claim 10, wherein said cells are selected from muscle and liver cells.
- 12. The method according to claim 6, wherein said carbohydrate is fat.
- 13. The method according to claim 12, wherein said active agent modulates triacylglycerol synthesis.
- 14. The method according to claim 13, wherein said active agent modulates levels of stored triacylglycerol in cells of said host.
- 15. The method according to claim 14, wherein said cells are adipocyte cells.
- 16. A method of treating a host suffering from a condition associated with abnormal carbohydrate metabolism, said method comprising:
administering to said host an effective amount of one or more active agents that modulate DGAT activity in said host and treat said host for said condition.
- 17. The method according to claim 16, wherein said agent modulates sensitivity to insulin and/or leptin.
- 18. The method according to claim 16, wherein said agent decreases DGAT1 activity in said host and the condition is obesity.
- 19. The method according to claim 18, wherein said treatment comprises a reduction of host weight and/or body fat.
- 20. The method according to claim 16, wherein said agent decreases DGAT activity in said host and the condition is diabetes.
- 21. The method according to claim 20, wherein said agent treatment comprises a stabilization of blood glucose levels.
- 22. The method according to claim 16, wherein said agent increases DGAT1 activity in said host and said condition is anorexia.
- 23. The method according to claim 16, wherein said host is a human.
- 24. The method according to claim 16, wherein said administering step comprises co-administering insulin and/or leptin or an activity mimetic thereof with an agent that modulates DGAT1 activity.
- 25. A pharmaceutical preparation comprising a DGAT1 activity modulatory agent in a pharmaceutically acceptable vehicle.
- 26. The pharmaceutical preparation according to claim 25, wherein said DGAT1 activity modulatory agent increases DGAT1 activity and decreases insulin and/or leptin sensitivity.
- 27. The pharmaceutical preparation according to claim 25, wherein said DGAT1 activity modulatory agent decreases DGAT1 activity and increases insulin and/or leptin sensitivity.
- 28. The pharmaceutical preparation according to claim 25, further comprising insulin, leptin or a mimetic thereof.
- 29. A kit comprising:
(a) a pharmaceutical preparation comprising at least one active DGAT1 modulatory agent; and (b) instructions for treating a host suffering from a condition associated with abnormal carbohydrate metabolism by administering to said host an effective amount of one or more active DGAT1 modulatory agents to treat said host for said condition.
- 30. The kit according to claim 29, wherein said one or more active DGAT1 modulatory agents reduce DGAT1 activity and said instructions are instructions for treating obesity and/or diabetes.
- 31. The kit according to claim 29, wherein said kit further includes insulin and/or leptin.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of application Ser. No. 10/040,315 filed Oct. 29, 2001; which application is: (a) a continuation-in-part of application Ser. No. 09/339,472 filed on Jun. 23, 1999, which application claims priority to the filing date of U.S. Provisional Patent Application Serial No. 60/107,771 filed Nov. 9, 1998; and (b) a continuation-in-part of PCT application Ser. No. PCT/US98/17883, filed Aug. 28, 1998, which application is a continuation in part of application Ser. No. 09/103,754, now U.S. Pat. No. 6,344,548, filed Jun. 24, 1998; the disclosures of which applications are herein incorporated by reference.
ACKNOWLEDGMENT OF GOVERNMENT SUPPORT
[0002] This invention was made with Government support under Grant Nos. DK-56084 and DK-26356 awarded by the National Institutes of Health. The Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60107771 |
Nov 1998 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
10040315 |
Oct 2001 |
US |
Child |
10289172 |
Nov 2002 |
US |
Parent |
09339472 |
Jun 1999 |
US |
Child |
10040315 |
Oct 2001 |
US |
Parent |
PCT/US98/17883 |
Aug 1998 |
US |
Child |
10040315 |
Oct 2001 |
US |
Parent |
09103754 |
Jun 1998 |
US |
Child |
PCT/US98/17883 |
Aug 1998 |
US |